Skip to main content

Top publication

Long-term monitoring of SARS-CoV-2 seroprevalence and variants in Ethiopia provides prediction for immunity and cross-immunity.

Nature communications

Authors: Simon Merkt, Solomon Ali, Esayas Kebede Gudina, Wondimagegn Adissu, Addisu Gize, Maximilian Muenchhoff, Alexander Graf, Stefan Krebs, Kira Elsbernd, Rebecca Kisch, Sisay Sirgu Betizazu, Bereket Fantahun, Delayehu Bekele, Raquel Rubio-Acero, Mulatu Gashaw, Eyob Girma, Daniel Yilma, Ahmed Zeynudin, Ivana Paunovic, Michael Hoelscher, Helmut Blum, Jan Hasenauer, Arne Kroidl, Andreas Wieser

Under-reporting of COVID-19 and the limited information about circulating SARS-CoV-2 variants remain major challenges for many African countries. We analyzed SARS-CoV-2 infection dynamics in Addis Ababa and Jimma, Ethiopia, focusing on reinfection, immunity, and vaccination effects. We conducted an antibody serology study spanning August 2020 to July 2022 with five rounds of data collection across a population of 4723, sequenced PCR-test positive samples, used available test positivity rates, and constructed two mathematical models integrating this data. A multivariant model explores variant dynamics identifying wildtype, alpha, delta, and omicron BA.4/5 as key variants in the study population, and cross-immunity between variants, revealing risk reductions between 24% and 69%. An antibody-level model predicts slow decay leading to sustained high antibody levels. Retrospectively, increased early vaccination might have substantially reduced infections during the delta and omicron waves in the considered group of individuals, though further vaccination now seems less impactful.

© 2024. The Author(s).

PMID: 38658564

Participating cluster members